Background: Fluorescent dye Rhodamine 6G (R6G) is a substrate of multidrug resistance pumps and its accumulation is reduced in some azole-resistant Candida isolates with the upregulation of multidrug efflux transporter genes. Despite reports on species-specific differences in azole susceptibility in various Candida species, only a few studies have been reported on the R6G accumulation among clinical isolates of Candida species. In this study, we compared R6G accumulation between six different Candida species.
Methods: The intracellular accumulation of R6G and minimal inhibitory concentrations (MICs) of three triazole agents were investigated in 48 strains of six Candida species (14 C. albicans, 9 C. tropicalis, 8 C. glabrata, 8 C. krusei, 7 C. parapsilosis, and 2 C. haemulonii). R6G accumulation was measured by using flow cytometry and the geometric mean of the fluorescence intensity (GMF) was used to compare the accumulation between the Candida isolates.
Results: The GMF values for the C. tropicalis, C. albicans, C. krusei, C. parapsilosis, and C. glabrata isolates were 167.3+/-18.5, 126.9+/-6.6, 88.5+/-18.5, 50.8+/-7.0, and 38.1+/-3.9, respectively. C. glabrata had a significantly lower mean GMF than all the other Candida species (P<0.05). While some Candida strains with trailing growth phenomenon and increased fluconazole MIC did not have a reduced GMF, three Candida strains with increased MICs to all three triazole agents had a reduced GMF.
Conclusions: This study found species-specific differences in R6G accumulation in Candida. In addition, the intracellular R6G accumulation can be used to investigate the drug efflux mechanism in azole-resistant Candida strains.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3343/kjlm.2009.29.2.127 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PMA1-containing extracellular vesicles of triggers immune responses and colitis progression.
Gut Microbes
December 2025
Department of Oncology, Nanjing Drum Tower Hospital, State Key Laboratory of Pharmaceutical Biotechnology, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
() exhibits aberrant changes in patients with colitis, and it has been reported to dominate the colonic mucosal immune response. Here, we found that PMA1 expression was significantly increased in from patients with IBD compared to that in healthy controls. A Crispr-Cas9-based fungal strain editing system was then used to knock out PMA1 expression in .
View Article and Find Full Text PDFSusceptibility patterns of species collected from intensive care units in Portugal: a prospective study in 2020-2022.
Infect Prev Pract
December 2024
Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science, 2829-511, Caparica, Almada, Portugal.
Background: For infections antifungal therapy is often empirical and mainly depends on locally antifungal surveillance data, which differs between geographic regions.
Aims: To monitor the epidemiology and antifungal susceptibility of spp. from combined axillar-groin samples in intensive care unit (ICU) patients on admission (day1, D1), day 5 (D5) and day 8 (D8).
Alterations of the Intestinal Mucosal Barrier and Gut Fungal Microbiome in Asymptomatic HIV-Infected Patients.
Can J Infect Dis Med Microbiol
December 2024
School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Damage to the intestinal mucosal barrier and dysbiosis of the gut microbiota are critical factors in HIV progression, reciprocally influencing each other. Besides bacteria, the fungal microbiota, a significant component of the gut, plays a pivotal role in this dysregulation. This study aims to investigate changes in the gut mucosal barrier and mycobiota during the initial stages of HIV infection, focusing on the involvement of intestinal fungi and their secretions in mucosal damage.
View Article and Find Full Text PDFAntimycobacterial and Antifungal Activities of Leaf Extracts From .
Scientifica (Cairo)
December 2024
Department of Therapeutics, Natural Products Unit, Wilkins Hospital Block C, Cnr J. Tongogara and R. Tangwena, The African Institute of Biomedical Research and Technology (AiBST), Harare, Zimbabwe.
The global problem of infectious and deadly diseases caused by microbes such as candida and mycobacteria presents major scientific and medical challenges. Antimicrobial drug resistance is a rapidly growing problem with potentially devastating consequences. Various pathogens can cause skin infections, such as bacteria, fungi, and parasites.
View Article and Find Full Text PDFAdvanced Peptide Nanozymes with Dual Antifungal Mechanisms: Cutting-Edge Innovations in Combatting Antimicrobial Resistance.
Curr Microbiol
January 2025
Department of Research Analytics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Poonamallee High Road, Chennai, Tamil Nadu, 600 077, India.
This letter commends the recent innovative research findings on "Dual-Action Antifungal Peptide Nanozymes: A Novel Approach to Combatting Antimicrobial Resistance." The study introduces a pioneering method to address antimicrobial resistance by developing peptide nanozymes that mimic antimicrobial peptides and enzymes through de novo design and peptide assembly. The heptapeptide IHIHICI, designed using AlphaFold2 and molecular dynamics simulations, exhibits high stability and dual antifungal actions, effectively killing over 90% of Candida albicans within 10 min.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!